Sources

8 Total Sources

Eli Lilly to Seek FDA Nod for Retatrutide After 22.6% Weight Loss in Phase 3

Left33%

Center50%

Right17%

Eli Lilly to Seek FDA Approval for Retatrutide Weight-Loss Drug in Q1 2027

Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application | Reuters

The Obesity Drug War Turns Ugly: Novo Nordisk Sues Eli Lilly and Wall Street Already Picked a Side - AOL

StockTitan21h ago

Eli Lilly Retatrutide Phase 3: Up to 22.6% Weight Loss | LLY Stock News

ELI LILLY TO FILE RETATRUTIDE FDA APPROVAL APPLICATION IN Q1 2027 PREVIOUSLY SOME SPECULATION THIS WOULD HAPPEN BY EOY 2026 $LLY $NVO $HIMS

1470 & 100.3 WMBD21h ago

Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application | 1470 & 100.3 WMBD

baha news21h ago

Eli Lilly to seek obesity drug approval in Q1 2027 - Breaking The News

Eli Lilly to File for Retatrutide Obesity Drug Approval in Q1 2027